Business Context and Reporting Period
This Form 8-K Current Report was filed by ADVENTRX Pharmaceuticals, Inc. (not Savara Inc.) on December 20, 2006. The filing reports the appointment of a new Chief Financial Officer and the departure of the Acting CFO.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on executive compensation and equity grants.
- New CFO Base Salary: $250,000 annually.
- Stock Option Grant: 250,000 shares of common stock.
- Option Exercise Price: Equal to the closing sales price on the American Stock Exchange on December 20, 2006.
Material Changes
The primary material change is the leadership transition in the finance department:
- Appointment: Gregory P. Hanson was appointed Senior Vice President, Chief Financial Officer, and Treasurer, effective immediately.
- Departure: Robert Daniel ceased serving as Acting Chief Financial Officer but will continue as Controller.
Guidance, Outlook, and Compensation Details
The filing details the compensatory arrangements for Mr. Hanson:
- Termination Benefits: In the event of involuntary termination, Mr. Hanson is entitled to six months of base salary and health/welfare/retirement benefits, payable in installments, subject to a general release of claims.
- Vesting Schedule: The stock option vests 25% on December 20, 2007, with the remainder vesting monthly (1/48th per month) thereafter, contingent on continuous service.
- Acceleration: Vesting accelerates upon involuntary termination or a change in control of the Company.
Investor Verification Checklist
- Verify the closing stock price on the American Stock Exchange on December 20, 2006, to determine the exercise price of the 250,000 options granted.
- Review the attached Exhibit 10.1 (Offer Letter) and Exhibit 10.2 (Stock Option Agreement) for specific definitions of "involuntary termination" and "change in control."
- Confirm the company's current cash position to assess the ability to fund the new CFO's salary and potential termination benefits.
- Check subsequent filings to confirm if Robert Daniel's role as Controller remains unchanged.